scispace - formally typeset
I

Iris L. Romero

Researcher at University of Chicago

Publications -  42
Citations -  6079

Iris L. Romero is an academic researcher from University of Chicago. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 21, co-authored 41 publications receiving 4662 citations.

Papers
More filters
Journal ArticleDOI

Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth

TL;DR: It is shown that primary human omental adipocytes promote homing, migration and invasion of ovarian cancer cells, and that adipokines including interleukin-8 (IL-8) mediate these activities, and adipocytes provide fatty acids for rapid tumor growth.
Journal ArticleDOI

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, +116 more
- 28 Oct 2017 - 
TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Journal ArticleDOI

Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer

TL;DR: This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015 and aims to reduce incidence and improve outcomes for women with this disease.
Journal ArticleDOI

Adipose tissue and adipocytes support tumorigenesis and metastasis.

TL;DR: Given that adipocytes are a major source of adipokines and energy for the cancer cell, understanding the mechanisms of metabolic symbiosis between cancer cells and adipocytes, should reveal new therapeutic possibilities.
Journal ArticleDOI

CD95 promotes tumour growth

TL;DR: It is shown that cancer cells in general, regardless of their CD95 apoptosis sensitivity, depend on constitutive activity of CD95, stimulated by cancer-produced CD95L, for optimal growth.